Dana-Farber research reveals encouraging pregnancy outcomes for breast cancer survivors

New research by Dana-Farber Cancer Institute investigators has encouraging news for young women who have survived breast cancer and want to have children.

The study, which tracked nearly 200 young women treated for breast cancer, found that the majority of those who tried to conceive during a median of 11 years after treatment were able to become pregnant and give birth to a child.

The findings, to be presented at the 2024 Annual Meeting of the American Society of Clinical Oncology (ASCO), are particularly noteworthy because they answer several questions left open by previous studies of pregnancy and live-birth rates among breast cancer survivors, the study authors say.

Earlier studies were limited because they included select subgroups of patients, followed patients for a relatively short period of time, and didn't ask participants, during the study period, if they had attempted pregnancy. This study was designed to address those gaps by tracking pregnancy and live birth rates among a group of breast cancer survivors and patients who indicated they'd attempted to conceive following their cancer diagnosis."

Ann Partridge, MD, MPH, study's senior author, founder and director of the Program for Young Adults with Breast Cancer at Dana-Farber

The patients in the study were participants in the Young Women's Breast Cancer Study, which is tracking the health of a group of women diagnosed with breast cancer at or under age 40. Of 1,213 eligible participants, 197 reported an attempt of pregnancy over a median follow-up period of 11 years. Within this latter group, the median age at the time of diagnosis was 32 years, and most were diagnosed with hormone receptor-positive breast cancer. Participants were periodically surveyed about whether they had tried to become pregnant and whether they had conceived and given birth.

Over the course of the study, 73% of women attempting to conceive achieved a pregnancy and 65% had a live birth, researchers found. Those who opted for fertility preservation by egg/embryo freezing before cancer treatment tended to have a higher live birth rate, while older participants tended to have lower pregnancy and live birth rates.

Participants in the study had breast cancers ranging from stage 0, which are non-invasive and confined to the inside of the milk duct, to stage III, in which the cancer has spread to the lymph nodes. Researchers found that the stage of the disease at diagnosis wasn't statistically associated with achieving a pregnancy or live birth.

"For many young women with breast cancer, the ability to have children following treatment is a major concern," says the study's first author, Kimia Sorouri, MD, MPH, of Dana-Farber. "The findings of our study can be helpful when counseling patients about fertility issues. The finding that egg/embryo freezing before treatment was associated with a higher live birth rate underscores the need for accessibility to fertility preservation services for this population."

This study was funded by Susan G. Komen and the Breast Cancer Research Foundation.


The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
AI-based liquid biopsy technology promises early detection of cancer recurrence